Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
08 Novembre 2023 - 2:00PM
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will participate at the following conferences:
Jefferies London Healthcare ConferenceFireside
Chat Date: Wednesday, November 15, 2023Fireside Chat Time: 3:00 PM
GMTLocation: Waldorf Hilton, London, UK
BTIG 3rd Annual
Ophthalmology DayFireside Chat Date: Monday, November 27,
2023Fireside Chat Time: 12:30 PM ETLocation: Virtual
Piper Sandler 35th
Annual Healthcare ConferenceFireside Chat Date:
Wednesday, November 29, 2023Fireside Chat Time: 1:00 PM ETLocation:
The Lotte New York Palace, New York, NY
Management will be available throughout the day for investor
meetings at all three conferences. If you plan to attend at least
one of the conferences and are interested in meeting with
management, please contact your BTIG, Jefferies, or Piper Sandler
representative.
A live webcast of the fireside chats can be accessed by visiting
the Investors section of the Company’s website at
investors.ocutx.com.
About Ocular Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company focused on
the formulation, development and commercialization of innovative
therapies for diseases and conditions of the eye using its
proprietary bioresorbable hydrogel-based formulation technology
ELUTYX™. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: AXPAXLI
(axitinib intravitreal implant), currently in a pivotal Phase 3
trial for wet AMD and a Phase 1 clinical trial for the treatment of
diabetic retinopathy; OTX-TIC (travoprost intracameral implant),
currently in a Phase 2 clinical trial for the treatment of primary
open-angle glaucoma or ocular hypertension; and OTX-CSI
(cyclosporine intracanalicular insert) for the chronic treatment of
dry eye disease and OTX-DED (dexamethasone intracanalicular insert)
for the short-term treatment of the signs and symptoms of dry eye
disease, both of which have completed Phase 2 clinical trials.
InvestorsOcular TherapeutixDonald NotmanChief
Financial Officerdnotman@ocutx.com
or
ICR WestwickeChris Brinzey, 339-970-2843Managing
Directorchris.brinzey@westwicke.com
MediaICR WestwickeBen Shannon,
443-213-0495ben.shannon@westwicke.com
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Lug 2023 a Lug 2024